A recent whole-exome sequencing analysis identified SLC30A8 as one of the top four genes that gave the strongest T2D gene-level signals for rare variants, establishing ZnT8 as a top target of prioritization for drug discovery (225). Here, SLC30A10 is linked to type 2 diabetes mellitus.